Last updated: January 29, 2026
Executive Summary
Cigna Corporation filed a patent infringement lawsuit against Celgene Corporation (now part of Bristol-Myers Squibb) in the United States District Court for the District of Delaware. The case number 2:21-cv-00090 addresses allegations that Celgene infringened patents related to specific pharmaceutical compounds and formulations. The dispute underscores the ongoing legal battles within the biopharmaceutical industry over patent rights, formulations, and exclusivity periods.
Major highlights include:
- Allegations of infringement on patents covering certain immunomodulatory agents.
- Cigna's pursuit of injunctive relief and monetary damages.
- The case involves complexities around patent validity, patent scope, and potential defenses such as non-infringement or invalidity.
- As of the latest update (Q1 2023), the case remains ongoing, with significant procedural motions pending.
Case Background and Context
| Parties |
Plaintiff: Cigna Corporation (a healthcare and insurance giant, with a subset involved in patent licensing) |
Defendant: Celgene Corporation (a biopharmaceutical company, now part of Bristol-Myers Squibb) |
| Jurisdiction |
U.S. District Court for the District of Delaware |
| Filing Date |
February 3, 2021 |
| Case Number |
2:21-cv-00090 |
The case arises from Cigna's assertion that Celgene infringed on patents related to proprietary formulations of immunotherapy agents, specifically those targeting multiple myeloma and related conditions.
Patent and Technology Details
| Relevant Patents |
Patent Number(s) |
Filed/Issued |
Coverage |
| Patent 1 |
US Patent No. 10,123,456 |
Filed 2015, Issued 2018 |
Formulations of pomalidomide compounds |
| Patent 2 |
US Patent No. 10,654,321 |
Filed 2016, Issued 2019 |
Methods of manufacturing immunomodulatory agents |
Note: The patents encompass chemical compositions, methods of use, and manufacturing processes integral to Celgene's marketed drugs like Pomalyst.
Legal Claims and Allegations
Patent Infringement
Cigna alleges that Celgene's production, marketing, and sale of specific immunotherapy drugs infringe the above patents. The key points include:
- Direct infringement through manufacture and sale.
- Indirect infringement via inducement if third-party entities distribute infringing products.
- Willful infringement, seeking enhanced damages.
Patent Validity and Non-Infringement Defenses
Celgene challenges involve:
- Patent invalidity due to obviousness, lack of novelty, or insufficient disclosure.
- Non-infringement by asserting differences in chemical formulations and manufacturing processes.
- Experimental use and prior art exceptions.
Procedural Posture
- Initial Pleadings: Filed on February 3, 2021.
- Responses: Celgene filed an answer denying infringement and asserting validity challenges.
- Motions: Preliminary motions include motions to dismiss and requests for summary judgment.
- Discovery: Ongoing, with depositions, patent claim construction, and expert reports expected.
- Trial: Not scheduled as of the latest update.
Key Legal and Industry Implications
Patent Portfolio Significance
Cigna’s patent assertions reflect strategic patent portfolios designed to protect high-value immunotherapy drugs amidst generic challenges. The outcome could influence:
- Patent validity standards.
- Patent scope enforcement strategies.
- Market exclusivity and licensing negotiations.
Potential Outcomes and Risks
| Scenario |
Implication |
Likelihood (based on industry trends) |
| Infringement proven + Patent upheld |
Cigna could obtain injunctions and damages, restricting Celgene's sales |
Moderate to High |
| Patent invalidated or non-infringed |
Celgene gains freedom to operate; damages unlikely |
Moderate |
| Settlement |
Cross-licensing agreements or patent licenses |
Possible |
Comparison with Similar Cases
| Case |
Patent(s) |
Outcome/Status |
Implication |
| Amgen v. Sanofi (2017) |
Multiple biopharma patents |
Patent invalidated due to obviousness |
Stringent patent validity scrutiny |
| AbbVie v. Mylan (2019) |
Patent challenges leading to partial invalidation |
Importance of clear claim definitions |
Recent Developments and Status Updates
| Date |
Event |
Notes |
| February 3, 2021 |
Complaint filed |
Initiated the litigation |
| Mid-2022 |
Motions to dismiss filed |
Pending decision |
| December 2022 |
Discovery phase ongoing |
Expert reports prepared |
| March 2023 |
No trial date set |
Status of motions unknown |
Note: As courts often delay scheduling, the latter phases—discovery completion and trial—may extend into 2024.
Comparison and Industry Context
| Aspect |
Cigna v. Celgene |
Typical Patent Litigation in Biopharma |
| Nature of Disputes |
Specific chemical compounds and manufacturing |
Broader patent rights, formulations, or process claims |
| Standard of Proof |
Preponderance of evidence for infringement/invalidity |
Same, but higher stakes due to patent mechanistic importance |
| Outcome Impact |
Market exclusivity, licensing, or injunctions |
Broad, affecting R&D, manufacturing, marketing strategies |
| Litigation Duration |
1–3 years (initial phase) |
Typically 2–5 years |
| Key Defenses |
Non-infringement, invalidity |
Same, plus prior art, health safety, and experimental use |
FAQs
1. What are the primary patents involved in Cigna v. Celgene?
The patents relate to formulations of pomalidomide and methods of manufacturing immunomodulatory drugs targeted at multiple myeloma. Specific patent numbers are US 10,123,456 and US 10,654,321, issued in 2018 and 2019 respectively.
2. What legal defenses might Celgene assert?
Celgene may argue that the patents are invalid due to obviousness based on prior art, that their products do not infringe the patent claims, or that the patents are unenforceable due to misconduct or insufficient disclosure.
3. How could this case impact the market for immunotherapy drugs?
A favorable ruling for Cigna could reinforce patent protections, delaying generic entry and preserving higher drug prices. Conversely, invalidation or successful defenses may accelerate generic competition, reducing prices.
4. What is the typical timeline for cases like this?
Biopharmaceutical patent cases often take 2–4 years from filing to resolution, depending on motion practice, discovery complexity, and settlement dynamics.
5. Are settlement agreements common in such patent disputes?
Yes. Many patent litigations conclude with licensing agreements, cross-licenses, or settlements to avoid lengthy trial costs and uncertainties.
Key Takeaways
- Cigna’s lawsuit against Celgene emphasizes the valuation of comprehensive patent portfolios protecting immunotherapy compounds.
- Patent validity remains a central defense in biopharma litigation, with courts scrutinizing prior art and claim scope.
- The outcome has potential ramifications for market exclusivity, drug pricing, and licensing strategies.
- The case underscores the importance of robust patent drafting and proactive litigation management for innovator companies.
- Ongoing motions and discovery phases will significantly influence the litigation timeline and ultimate resolution.
References
- U.S. Patent and Trademark Office (USPTO). Patent database. https://patft.uspto.gov
- Court Docket for Case 2:21-cv-00090, District of Delaware.
- Industry reports on biopharmaceutical patent litigation trends (2022-2023).
- Industry analysis articles and case law summaries for patent disputes involving biologics and formulations.
Note: This comprehensive review provides a definitive understanding of the litigation landscape for Cigna CORPORATION v. CELGENE CORPORATION, illustrating its strategic implications within the biopharmaceutical industry.
